Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase ii trial in men with metastatic castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Itraconazole
  • Prostatic Neoplasms, Castration-Resistant

abstract

  • High-dose itraconazole (600 mg/day) has modest antitumor activity in men with metastatic CRPC that is not mediated by testosterone suppression.

publication date

  • March 4, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3579600

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2012-314

PubMed ID

  • 23340005

Additional Document Info

start page

  • 163

end page

  • 73

volume

  • 18

number

  • 2